Home > Boards > US Listed > Medical - Drugs > Relmada Therapeutics Inc. (RLMD)

NEWS -- Relmada Therapeutics Announces Uplisting to the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 75
Posts 10,612
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/5/2021 4:09:28 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/31/2021 5:02:19 PM
Relmada Therapeutics EPS misses by $0.25 Seeking Alpha - 3/23/2021 4:31:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:17:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:14:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:52:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:51:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2021 6:19:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2021 4:08:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 5:07:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:59:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:55:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/17/2021 6:38:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:52:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:22:22 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:16:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 9:39:36 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 8:06:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:42:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:40:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/3/2021 6:35:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2021 5:06:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/2/2021 3:15:45 PM
Paulness   Monday, 07/13/20 09:15:44 AM
Re: None
Post # of 500 
NEWS -- Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."

The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com

For Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-global-select-market-301092149.html

SOURCE Relmada Therapeutics, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences